Jeevan Scientific Technology Receives 'Sell' Rating

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has recently received a 'Sell' rating from MarketsMOJO on January 2nd, 2024. This downgrade is based on the company's poor long-term growth, with an annual operating profit growth rate of -213.67% over the past 5 years.
In addition, the company's recent financial results for September 2023 have been flat, indicating a lack of growth potential. The stock is also considered risky due to its negative operating profits and below-average historical valuations.

Furthermore, Jeevan Scientific Technology has underperformed the market in the last year, with a return of only 3.68% compared to the BSE 500's return of 24.19%. This further supports the 'Sell' rating given by MarketsMOJO.

However, the company does have a strong ability to service debt, with a low Debt to EBITDA ratio of 0.86 times. Additionally, the stock is currently in a Mildly Bullish range, with technical factors such as MACD and Bollinger Bands also showing a Bullish trend.

It is worth noting that the majority of shareholders in Jeevan Scientific Technology are non-institutional investors. This could potentially lead to higher volatility in the stock price.

Overall, while Jeevan Scientific Technology may have some positive aspects, the recent downgrade to a 'Sell' rating by MarketsMOJO suggests that investors should approach this stock with caution.